Français | English

Agence nationale sanitaire et scientifique en cancérologie

Accueil Nota Bene Cancer V2 Numéro 131 du 11 April 2012 Dépistage, diagnostic et pronostic

Print

Nota Bene Cancer Numéro 131 du 11 April 2012 RSS

Dépistage, diagnostic et pronostic

Découverte de technologies et de biomarqueurs

Menée à l'aide d'une biopuce sur des échantillons tumoraux prélevés, avant et après un traitement au bevacizumab, sur 21 patients atteints d'un glioblastome, cette étude identifie deux profils de résistance à une thérapie anti-angiogénique

  • Détails
    Fermer

    Menée à l'aide d'une biopuce sur des échantillons tumoraux prélevés, avant et après un traitement au bevacizumab, sur 21 patients atteints d'un glioblastome, cette étude identifie deux profils de résistance à une thérapie anti-angiogénique

    “Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to anti-angiogenic therapy”

    • De Lay, Michael;Jahangiri, Arman;Carbonell, W. Shawn;Hu, Yu-Long;Tsao, Sean;Tom, Maxwell Wing;Paquette, Jesse;Tokuyasu, Taku;Aghi, Manish K

    Purpose: To identify mechanisms and mediators of resistance to anti-angiogenic therapy in human glioblastoma. Experimental Design: We performed microarray gene expression analysis and immunohistochemistry comparing 21 recurrent glioblastomas progressing during anti-angiogenic treatment with VEGF neutralizing antibody bevacizumab to paired pre-treatment tumors from the same patients. Results: Microarray analysis revealed that bevacizumab-resistant glioblastomas (BRGs) had 2 clustering patterns defining subtypes that reflect radiographic growth patterns. Enhancing BRGs (EBRGs) exhibited MRI enhancement, a long-established criterion for glioblastoma progression, and expressed mitogen-activated protein kinases, neural cell adhesion molecule-1 (NCAM-1), and aquaporin 4. Compared to their paired pre-treatment tumors, EBRGs had unchanged vascularity and hypoxia, with increased proliferation. Non-enhancing BRGs (NBRGs) exhibited minimal MRI enhancement but had FLAIR-bright expansion, a newer ...


Mots clés : Système nerveux central; Dépistage, diagnostic et pronostic (Découverte de technologies et de biomarqueurs)

Menée sur 415 patients atteints d'une leucémie myéloïde aiguë, cette étude évalue l'association entre des mutations somatiques du gène DNMT3A et la survie des patients

  • Détails
    Fermer

    Menée sur 415 patients atteints d'une leucémie myéloïde aiguë, cette étude évalue l'association entre des mutations somatiques du gène DNMT3A et la survie des patients

    “Mutant DNMT3A: a new marker of poor prognosis in acute myeloid leukemia”

    • Ribeiro, Ana Flávia Tibúrcio;Pratcorona, Marta;Erpelinck-Verschueren, Claudia;Rockova, Veronika;Sanders, Mathijs;Abbas, Saman;Figueroa, Maria E.;Zeilemaker, Annelieke;Melnick, Ari;Löwenberg, Bob;Valk, Peter J. M.;Delwel, Ruud

    The prevalence, the prognostic impact and interaction with other molecular markers of DNMT3A mutations was studied in 415 patients with acute myeloid leukemia (AML) younger than 60 years. We demonstrate mutations in DNMT3A in 96/415 newly diagnosed AML patients (23.1%). Univariable Cox regression analysis demonstrated that DNMT3Amutant patients show significantly worse overall survival (OS:P=.022;hazard ratio [HR]=1.38;CI=1.04-1.81), and relapse-free survival (RFS:P=.005;HR=1.52;CI=1.13-2.05) than DNMT3Awild-type AMLs. In a multivariable analysis, DNMT3A mutations express independent unfavourable prognostic value as regards OS (P=.003;HR=1.82;CI=1.2-2.7) and RFS (P<.001;HR=2.2;CI=1.4-3.3) as well. In a composite genotypic subset of cytogenetic intermediate-risk AML without FLT3-ITD and NPM1 mutations this association is particularly evident (OS:P=.013;HR=2.09;CI=1.16-3.77;RFS:P=.001;HR=2.65;CI=1.48-4.89). The effect of DNMT3A mutations in human AML remains elusive, since DNMT3Amutant ...


Mots clés : Leucémie; Dépistage, diagnostic et pronostic (Découverte de technologies et de biomarqueurs)

Cette étude évalue la faisabilité et l'intérêt d'un dispositif à base de microfluidique pour mener des études de protéomique

  • Microfluidic integration for automated targeted proteomic assays
    Proceedings of the National Academy of Sciences, sous presse, 2012 (résumé)
    Détails
    Fermer

    Cette étude évalue la faisabilité et l'intérêt d'un dispositif à base de microfluidique pour mener des études de protéomique

    “Microfluidic integration for automated targeted proteomic assays”

    • Hughes, Alex J.;Lin, Robert K. C.;Peehl, Donna M.;Herr, Amy E.

    A dearth of protein isoform-based clinical diagnostics currently hinders advances in personalized medicine. A well-organized protein biomarker validation process that includes facile measurement of protein isoforms would accelerate development of effective protein-based diagnostics. Toward scalable protein isoform analysis, we introduce a microfluidic “single-channel, multistage” immunoblotting strategy. The multistep assay performs all immunoblotting steps: separation, immobilization of resolved proteins, antibody probing of immobilized proteins, and all interim wash steps. Programmable, low-dispersion electrophoretic transport obviates the need for pumps and valves. A three-dimensional bulk photoreactive hydrogel eliminates manual blotting. In addition to simplified operation and interfacing, directed electrophoretic transport through our 3D nanoporous reactive hydrogel yields superior performance over the state-of-the-art in enhanced capture efficiency (on par with membrane ...


Mots clés : Cancer (général); Dépistage, diagnostic et pronostic (Découverte de technologies et de biomarqueurs)

Evaluation des technologies et des biomarqueurs

Cet article passe en revue les travaux récents sur les mécanismes de résistance aux taxanes utilisés pour le traitement d'un cancer du sein et les biomarqueurs prédictifs de la réponse thérapeutique

  • Détails
    Fermer

    Cet article passe en revue les travaux récents sur les mécanismes de résistance aux taxanes utilisés pour le traitement d'un cancer du sein et les biomarqueurs prédictifs de la réponse thérapeutique

    “Taxane resistance in breast cancer: Mechanisms, predictive biomarkers and circumvention strategies”

    • Murray, S.;Briasoulis, E.;Linardou, H.;Bafaloukos, D.;Papadimitriou, C.

    Taxanes are established in the treatment of metastatic beast cancer (MBC) and early breast cancer (EBC) as potent chemotherapy agents. However, their therapeutic usefulness is limited by de-novo refractoriness or acquired resistance, which are common drawbacks to most anti-cancer cytotoxics. Considering that the taxanes will remain principle chemotherapeutic agents for the treatment of breast cancer, we reviewed known mechanisms of resistance in with an outlook of optimizing their clinical use. We searched the PubMed and MEDLINE databases for articles (from inception through to 9th January 2012; last search 10/01/2012) and journals known to publish information relevant to taxane chemotherapy. We imposed no language restrictions. Search terms included: cancer, breast cancer, response, resistance, taxane, paclitaxel, docetaxel, taxol. Due to the possibility of alternative mechanisms of resistance all combination chemotherapy treated data sets were removed from our overview. ...


Mots clés : Sein; Dépistage, diagnostic et pronostic (Evaluation des technologies et des biomarqueurs)

Cet article passe en revue les travaux récents sur le développement de tests mesurant le niveau du domaine extracellulaire du récepteur HER2 dans le sérum des patientes

  • Challenges in the clinical utility of the serum test for HER2 ECD
    Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, sous presse, 2012 (résumé)
    Détails
    Fermer

    Cet article passe en revue les travaux récents sur le développement de tests mesurant le niveau du domaine extracellulaire du récepteur HER2 dans le sérum des patientes

    “Challenges in the clinical utility of the serum test for HER2 ECD”

    • Lam, Lian;McAndrew, Nicholas;Yee, Marla;Fu, Ting;Tchou, Julia C.;Zhang, Hongtao

    Approximately 15-30% of breast cancers over-express the HER2/neu receptor. Historically, over-expression of HER2/neu has been identified using IHC or FISH, both of which are invasive approaches requiring tissue samples. Recent evidence has shown that some tumors identified as “negative” using these methods can respond to HER2/neu targeted therapy. Shedding of the extracellular domain (ECD) of the receptor into the circulation has led to the development of serum test of HER2 ECD as an additional approach to probe HER2/neu overexpression. The serum test will be able to monitor the dynamic changes of HER2 status over the course of disease progression. Some studies further suggest that the serum HER2 ECD level and its change may serve as a biomarker to reflect patients’ response to therapy. Yet more than 10 years after the first serum HER2 ECD test was approved by the FDA, serum HER2 testing has yet to be widely used in clinical practice. In this article we will review the ...


Mots clés : Sein; Dépistage, diagnostic et pronostic (Evaluation des technologies et des biomarqueurs)

Menée sur 41 patients atteints d'un cancer avancé du poumon non à petites cellules et inclus dans un essai de phase II évaluant l'erlotinib et le pertuzumab, cette étude évalue l'intérêt de mesurer le nombre de cellules tumorales circulantes et d'ADN tumoral circulant pour suivre en temps réel la réponse thérapeutique

  • Détails
    Fermer

    Menée sur 41 patients atteints d'un cancer avancé du poumon non à petites cellules et inclus dans un essai de phase II évaluant l'erlotinib et le pertuzumab, cette étude évalue l'intérêt de mesurer le nombre de cellules tumorales circulantes et d'ADN tumoral circulant pour suivre en temps réel la réponse thérapeutique

    “Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib”

    • Punnoose, Elizabeth A.;Atwal, Siminder;Liu, Weiqun;Raja, Rajiv;Fine, Bernard M.;Hughes, Brett G.M.;Hicks, Rodney J.;Hampton, Garret M.;Amler, Lukas C.;Pirzkall, Andrea;Lackner, Mark R.

    Purpose: Elevated levels or increases in circulating tumor cells (CTC) portend poor prognosis in patients with epithelial cancers. Less is known about CTCs as surrogate endpoints or their use for predictive biomarker evaluation. This study investigated the utility of CTC enumeration and characterization using the CellSearch platform, as well as mutation detection in circulating tumor DNA (ctDNA), in patients with advanced non–small cell lung cancer (NSCLC).Experimental Design: Forty-one patients were enrolled in a single-arm phase II clinical trial of erlotinib and pertuzumab. Peripheral blood was analyzed for CTC enumeration, EGFR expression in CTCs, and detection of oncogenic mutations in CTCs and ctDNA. Changes in CTC levels were correlated with 2[18F]fluoro-2-deoxy-d-glucose–positron emission tomographic (FDG-PET) and computed tomographic (CT) imaging and survival endpoints.Results: CTCs were detected (≥1 CTC) at baseline in 78% of patients. Greater sensitivity for mutation ...


Mots clés : Poumon; Dépistage, diagnostic et pronostic (Evaluation des technologies et des biomarqueurs)

Menée sur 80 échantillons tumoraux prélevés sur des patientes atteintes d'un carcinome de l'ovaire, cette étude identifie une signature basée sur l'expression de 11 gènes en association avec le pronostic de la maladie chez les patientes recevant un traitement à base de carboplatine et paclitaxel

  • Détails
    Fermer

    Menée sur 80 échantillons tumoraux prélevés sur des patientes atteintes d'un carcinome de l'ovaire, cette étude identifie une signature basée sur l'expression de 11 gènes en association avec le pronostic de la maladie chez les patientes recevant un traitement à base de carboplatine et paclitaxel

    “Multidrug Resistance-Linked Gene Signature Predicts Overall Survival of Patients With Primary Ovarian Serous Carcinoma”

    • Gillet, Jean-Pierre;Calcagno, Anna Maria;Varma, Sudhir;Davidson, Ben;Bunkholt Elstrand, Mari;Ganapathi, Ram;Kamat, Aparna;Sood, Anil K.;Ambudkar, Suresh V.;Seiden, Michael;Rueda, Bo R;Gottesman, Michael M.

    Purpose: This study assesses the ability of multidrug resistance (MDR)-associated gene expression patterns to predict survival in patients with newly diagnosed carcinoma of the ovary. The scope of this research differs substantially from that of previous reports, as a very large set of genes was evaluated whose expression has been shown to affect response to chemotherapy. Experimental Design: We applied a customized TaqMan Low Density Array, a highly sensitive and specific assay, to study the expression profiles of 380 MDR-linked genes in 80 tumor specimens collected at initial surgery to debulk primary serous carcinoma. The RNA expression profiles of these drug resistance genes were correlated with clinical outcomes. Results: Leave-one-out cross-validation was used to estimate the ability of MDR gene expression to predict survival. Although gene expression alone does not predict overall survival (P=0.06), four covariates (age, stage, CA125 level and surgical debulking) do (P=0.03). ...


Mots clés : Ovaire; Dépistage, diagnostic et pronostic (Evaluation des technologies et des biomarqueurs)

Menée in vivo, cette étude évalue l'intérêt d'une technique de spectroscopie pour faciliter le diagnostic des cancers cutanés

  • Détails
    Fermer

    Menée in vivo, cette étude évalue l'intérêt d'une technique de spectroscopie pour faciliter le diagnostic des cancers cutanés

    “In vivo diagnosis of melanoma and non-melanoma skin cancer using oblique incidence diffuse reflectance spectrometry”

    • Garcia-Uribe, Alejandro;Zou, Jun;Duvic, Madeleine;Cho-Vega, Jeong Hee;Prieto, Victor G.;Wang, Lihong V.

    Early detection and treatment of skin cancer can significantly improve patient outcome. However, present standards for diagnosis require biopsy and histopathologic examinations that is relatively invasive, expensive and difficult for patients with many early stage lesions. Here we show an oblique incidence diffuse reflectance spectroscopic (OIDRS) system that can be used for rapid skin cancer detection in vivo. This system was tested under clinical conditions by obtaining spectra from pigmented and non-pigmented skin lesions, including melanomas, differently staged dysplastic nevi and common nevi that were validated by standard patho-histological criteria. For diagnosis of pigmented melanoma, the data obtained achieved 90% sensitivity and specificity for a blinded test set. In a second analysis, we demonstrated that this spectroscopy system can also differentiate non-pigmented basal cell or squamous cell carcinomas from non-cancerous skin abnormalities such as actinic keratoses and ...


Mots clés : Mélanome; Dépistage, diagnostic et pronostic (Evaluation des technologies et des biomarqueurs)

Cet article passe en revue les travaux récents sur l'intérêt de la tomographie à cohérence optique pour l'imagerie des cancers et, notamment, le suivi de la réponse thérapeutique

  • Détails
    Fermer

    Cet article passe en revue les travaux récents sur l'intérêt de la tomographie à cohérence optique pour l'imagerie des cancers et, notamment, le suivi de la réponse thérapeutique

    “Cancer imaging by optical coherence tomography: preclinical progress and clinical potential”

    • Vakoc, Benjamin J.;Fukumura, Dai;Jain, Rakesh K.;Bouma, Brett E.

    The past decade has seen dramatic technological advances in the field of optical coherence tomography (OCT) imaging. These advances have driven commercialization and clinical adoption in ophthalmology, cardiology and gastrointestinal cancer screening. Recently, an array of OCT-based imaging tools that have been developed for preclinical intravital cancer imaging applications has yielded exciting new capabilities to probe and to monitor cancer progression and response in vivo. Here, we review these results, forecast the future of OCT for preclinical cancer imaging and discuss its exciting potential to translate to the clinic as a tool for monitoring cancer therapy.


Mots clés : Cancer (général); Dépistage, diagnostic et pronostic (Evaluation des technologies et des biomarqueurs)

Menée à l'aide d'un modèle statistique, cette étude évalue l'intérêt du séquençage du génome entier d'un individu en population générale pour prédire sa prédisposition aux maladies les plus communes, notamment le cancer

  • The Predictive Capacity of Personal Genome Sequencing
    Science Translational Medicine, sous presse, 2012 (résumé)
    Détails
    Fermer

    Menée à l'aide d'un modèle statistique, cette étude évalue l'intérêt du séquençage du génome entier d'un individu en population générale pour prédire sa prédisposition aux maladies les plus communes, notamment le cancer

    “The Predictive Capacity of Personal Genome Sequencing”

    • Roberts, Nicholas J.;Vogelstein, Joshua T.;Parmigiani, Giovanni;Kinzler, Kenneth W.;Vogelstein, Bert;Velculescu, Victor E.

    New DNA sequencing methods will soon make it possible to identify all germline variants in any individual at a reasonable cost. However, the ability of whole-genome sequencing to predict predisposition to common diseases in the general population is unknown. To estimate this predictive capacity, we use the concept of a “genometype”. A specific genometype represents the genomes in the population conferring a specific level of genetic risk for a specified disease. Using this concept, we estimated the capacity of whole-genome sequencing to identify individuals at clinically significant risk for 24 different diseases. Our estimates were derived from the analysis of large numbers of monozygotic twin pairs; twins of a pair share the same genometype and therefore identical genetic risk factors. Our analyses indicate that: (i) for 23 of the 24 diseases, the majority of individuals will receive negative test results, (ii) these negative test results will, in general, not be very ...


Mots clés : Cancer (général); Dépistage, diagnostic et pronostic (Evaluation des technologies et des biomarqueurs)

Essais de technologies et de biomarqueurs dans un contexte clinique

Menée à partir de données danoises portant sur 58 003 participantes en bonne santé et âgées de 50 à 69 ans, cette étude évalue le risque de cancer du sein après un examen mammographique dont le résultat est faussement positif

  • Risk of Breast Cancer After False-Positive Test Results in Screening Mammography
    Journal of the National Cancer Institute, sous presse, 2012 (résumé)
    Détails
    Fermer

    Menée à partir de données danoises portant sur 58 003 participantes en bonne santé et âgées de 50 à 69 ans, cette étude évalue le risque de cancer du sein après un examen mammographique dont le résultat est faussement positif

    “Risk of Breast Cancer After False-Positive Test Results in Screening Mammography”

    • von Euler-Chelpin, My;Risør, Louise Madeleine;Thorsted, Brian Larsen;Vejborg, Ilse

    Background : Screening for disease in healthy people inevitably leads to some false-positive tests in disease-free individuals. Normally, women with false-positive screening tests for breast cancer are referred back to routine screening. However, the long-term outcome for women with false-positive tests is unknown. Methods : We used data from a long-standing population-based screening mammography program in Copenhagen, Denmark, to determine the long-term risk of breast cancer in women with false-positive tests. The age-adjusted relative risk (RR) of breast cancer for women with a false-positive test compared with women with only negative tests was estimated with Poisson regression, adjusted for age, and stratified by screening round and technology period. All statistical tests were two-sided. Results : A total of 58 003 women, aged 50–69 years, were included in the analysis. Women with negative tests had an absolute cancer rate of 339/100 000 person-years at risk, whereas women ...


Mots clés : Sein; Dépistage, diagnostic et pronostic (Essais de technologies et de biomarqueurs dans un contexte clinique)

Menée sur 184 patientes atteintes d'un cancer du sein diagnostiqué entre 2004 et 2008, cette étude montre qu'une stadification pré-opératoire de la maladie au moyen de l'imagerie par résonance magnétique et d'une biopsie de contrôle améliore les résultats des traitements chirurgicaux sans augmenter le taux de mastectomie

  • Détails
    Fermer

    Menée sur 184 patientes atteintes d'un cancer du sein diagnostiqué entre 2004 et 2008, cette étude montre qu'une stadification pré-opératoire de la maladie au moyen de l'imagerie par résonance magnétique et d'une biopsie de contrôle améliore les résultats des traitements chirurgicaux sans augmenter le taux de mastectomie

    “Preoperative Staging with Magnetic Resonance Imaging, with Confirmatory Biopsy, Improves Surgical Outcomes in Women with Breast Cancer without Increasing Rates of Mastectomy”

    • Grady, Ian;Gorsuch-Rafferty, Heidi;Hadley, Pat

    Abstract: Needle biopsy to evaluate findings on MRI that could alter surgical planning has been recommended. This study is a retrospective review to evaluate MRI preoperative staging with biopsy confirmation of suspicious findings. A total of 184 women were diagnosed with breast cancer between January 2004 and June 2008. Of these, 79 underwent bilateral MRI before definitive surgery and 105 did not. Suspicious findings on MRI, mammography, or clinical exam underwent additional needle biopsy at the discretion of the surgeon. A retrospective chart review was performed to compare the two groups with respect to rates of reoperative surgery, successful breast conservation, and confirmatory biopsies. Sensitivity and specificity of MRI for preoperative staging is 0.81 and 0.84, respectively. There were no significant differences in demographics or cancer characteristics between the MRI and non-MRI groups. Fewer women who underwent preoperative MRI staging required repeat breast surgery (11% ...


Mots clés : Sein; Dépistage, diagnostic et pronostic (Essais de technologies et de biomarqueurs dans un contexte clinique)

Mené entre 2004 et 2006 sur 2 662 femmes présentant un risque élevé de cancer du sein (durée de suivi : 12 mois), cet essai multicentrique évalue l'intérêt de compléter une mammographie par une échographie ou une IRM annuelle pour détecter précocement la maladie

  • Detection of Breast Cancer With Addition of Annual Screening Ultrasound or a Single Screening MRI to Mammography in Women With Elevated Breast Cancer Risk
    JAMA: The Journal of the American Medical Association, Vol. 307 (13), pp. 1394-1404, 2012 (résumé)
    Détails
    Fermer

    Mené entre 2004 et 2006 sur 2 662 femmes présentant un risque élevé de cancer du sein (durée de suivi : 12 mois), cet essai multicentrique évalue l'intérêt de compléter une mammographie par une échographie ou une IRM annuelle pour détecter précocement la maladie

    “Detection of Breast Cancer With Addition of Annual Screening Ultrasound or a Single Screening MRI to Mammography in Women With Elevated Breast Cancer Risk”

    • Berg, Wendie A.;Zhang, Zheng;Lehrer, Daniel;Jong, Roberta A.;Pisano, Etta D.;Barr, Richard G.;Böhm-Vélez, Marcela;Mahoney, Mary C.;Evans, W. Phil;Larsen, Linda H.;Morton, Marilyn J.;Mendelson, Ellen B.;Farria, Dione M.;Cormack, Jean B.;Marques, Helga S.;Adams, Amanda;Yeh, Nolin M.;Gabrielli, Glenna

    Context Annual ultrasound screening may detect small, node-negative breast cancers that are not seen on mammography. Magnetic resonance imaging (MRI) may reveal additional breast cancers missed by both mammography and ultrasound screening.Objective To determine supplemental cancer detection yield of ultrasound and MRI in women at elevated risk for breast cancer.Design, Setting, and Participants From April 2004-February 2006, 2809 women at 21 sites with elevated cancer risk and dense breasts consented to 3 annual independent screens with mammography and ultrasound in randomized order. After 3 rounds of both screenings, 612 of 703 women who chose to undergo an MRI had complete data. The reference standard was defined as a combination of pathology (biopsy results that showed in situ or infiltrating ductal carcinoma or infiltrating lobular carcinoma in the breast or axillary lymph nodes) and 12-month follow-up.Main Outcome Measures Cancer detection rate (yield), sensitivity, specificity, ...


Mots clés : Sein; Dépistage, diagnostic et pronostic (Essais de technologies et de biomarqueurs dans un contexte clinique)

A partir de l'analyse immunohistochimique d'échantillons tumoraux ou de tissus sains prélevés respectivement sur 181 patients atteints d'un cancer du poumon non à petites cellules réséqué et sur 20 témoins, cette étude évalue l'association entre l'expression de l'oncogène TAZ, des paramètres clinico-pathologiques et la survie globale des patients

  • Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer
    Journal of Thoracic Oncology, sous presse, 2012 (résumé)
    Détails
    Fermer

    A partir de l'analyse immunohistochimique d'échantillons tumoraux ou de tissus sains prélevés respectivement sur 181 patients atteints d'un cancer du poumon non à petites cellules réséqué et sur 20 témoins, cette étude évalue l'association entre l'expression de l'oncogène TAZ, des paramètres clinico-pathologiques et la survie globale des patients

    “Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer”

    • Xie, Mian;Zhang, Li;He, Chao-Sheng;Hou, Jin-Hui;Lin, Su-Xia;Hu, Zhi-Huang;Xu, Fei;Zhao, Hong-Yun

    Introduction: Transcriptional coactivator with PDZ-binding motif (TAZ) is known to bind to a variety of transcription factors to control cell differentiation and organ development. Recently, TAZ has been identified as an oncogene and has an important role in tumorigenicity of non-small cell lung cancer (NSCLC). Therefore, TAZ may present a novel target for the future diagnosis, prognosis, and therapy for lung cancer. We investigated the relationship between TAZ expression and clinicopathological parameters and determined its prognostic significance concerning survival in patients with resected NSCLC. Methods: TAZ expression was immunohistochemically studied in 181 consecutive patients with NSCLC and 20 cases of normal lung tissue. The association between expression of TAZ and clinicopathological parameters was evaluated. Kaplan-Meier survival analysis and Cox proportional hazards models were used to estimate the effect of TAZ expression on survival. Results: TAZ expression was ...


Mots clés : Poumon; Dépistage, diagnostic et pronostic (Essais de technologies et de biomarqueurs dans un contexte clinique)

Politiques et programmes de dépistage

A partir d'une revue systématique de la littérature publiée jusqu'en 2011 (23 études), cette méta-analyse évalue l'association entre l'indice de masse corporelle et le taux de participation à un dépistage du cancer colorectal

  • Body Mass Index and Colon Cancer Screening: A Systematic Review and Meta-Analysis
    Cancer Epidemiology Biomarkers & Prevention, sous presse, 2012 (résumé)
    Détails
    Fermer

    A partir d'une revue systématique de la littérature publiée jusqu'en 2011 (23 études), cette méta-analyse évalue l'association entre l'indice de masse corporelle et le taux de participation à un dépistage du cancer colorectal

    “Body Mass Index and Colon Cancer Screening: A Systematic Review and Meta-Analysis”

    • Maruthur, Nisa M.;Bolen, Shari;Gudzune, Kimberly;Brancati, Frederick L.;Clark, Jeanne M.

    Background: Obesity is associated with increased colon cancer mortality and lower rates of mammography and Pap testing.Methods: We conducted a systematic review to determine whether obesity is associated with lower rates of colon cancer screening. We searched the PubMed, CINAHL, and Cochrane Library databases. Two investigators reviewed citations, abstracts, and articles independently. Two investigators abstracted study information sequentially and evaluated quality independently using standardized forms. We included all studies in our qualitative syntheses. We used random effects meta-analyses to combine those studies providing screening results by the following body mass index (BMI) categories: Normal, 18.5–24.9 kg/m2 (reference); overweight, 25–29.9 kg/m2; class I obesity, 30–34.9 kg/m2; class II obesity, 35–39.9 kg/m2; and class III obesity, ≥ 40 kg/m2.Results: Of 5,543 citations, we included 23 articles. Almost all studies were cross-sectional and ascertained BMI and ...


Mots clés : Colon-rectum; Dépistage, diagnostic et pronostic (Politiques et programmes de dépistage)

Menée aux Etats-Unis sur 997 participants, cette étude évalue l'association entre deux recommandations pour le dépistage du cancer colorectal, par coloscopie ou par détection du sang occulte dans les selles, et l'adhésion au dépistage

  • Adherence to Colorectal Cancer Screening: A Randomized Clinical Trial of Competing Strategies
    Archives of Internal Medicine, Vol. 172 (7), pp. 575-582, 2012 (résumé)
    Détails
    Fermer

    Menée aux Etats-Unis sur 997 participants, cette étude évalue l'association entre deux recommandations pour le dépistage du cancer colorectal, par coloscopie ou par détection du sang occulte dans les selles, et l'adhésion au dépistage

    “Adherence to Colorectal Cancer Screening: A Randomized Clinical Trial of Competing Strategies”

    • Inadomi, John M.;Vijan, Sandeep;Janz, Nancy K.;Fagerlin, Angela;Thomas, Jennifer P.;Lin, Yunghui V.;Munoz, Roxana;Lau, Chim;Somsouk, Ma;El-Nachef, Najwa;Hayward, Rodney A.

    Background Despite evidence that several colorectal cancer (CRC) screening strategies can reduce CRC mortality, screening rates remain low. This study aimed to determine whether the approach by which screening is recommended influences adherence. Methods We used a cluster randomization design with clinic time block as the unit of randomization. Persons at average risk for development of CRC in a racially/ethnically diverse urban setting were randomized to receive recommendation for screening by fecal occult blood testing (FOBT), colonoscopy, or their choice of FOBT or colonoscopy. The primary outcome was completion of CRC screening within 12 months after enrollment, defined as performance of colonoscopy, or 3 FOBT cards plus colonoscopy for any positive FOBT result. Secondary analyses evaluated sociodemographic factors associated with completion of screening. Results A total of 997 participants were enrolled; 58% completed the CRC screening strategy they were assigned or chose. ...


  • The Importance of Choosing Colorectal Cancer Screening Tests: Comment on "Adherence to Colorectal Cancer Screening"
    Archives of Internal Medicine, Vol. 172 (7), pp. 582-583, 2012 (commentaire)
    Détails
    Fermer

    Menée aux Etats-Unis sur 997 participants, cette étude évalue l'association entre deux recommandations pour le dépistage du cancer colorectal, par coloscopie ou par détection du sang occulte dans les selles, et l'adhésion au dépistage

    “The Importance of Choosing Colorectal Cancer Screening Tests: Comment on "Adherence to Colorectal Cancer Screening"”

    • Levin, Theodore R.


Mots clés : Colon-rectum; Dépistage, diagnostic et pronostic (Politiques et programmes de dépistage)

Ressources et infrastructures (Dépistage)

Cet article passe en revue les problèmes posés par la nécessité d'informer les patientes sur les risques associés à un carcinome canalaire in situ pour améliorer la prise de décision thérapeutique

  • Challenges in ductal carcinoma in situ risk communication and decision-making
    CA: A Cancer Journal for Clinicians, sous presse, 2012 (article en libre accès)
    Détails
    Fermer

    Cet article passe en revue les problèmes posés par la nécessité d'informer les patientes sur les risques associés à un carcinome canalaire in situ pour améliorer la prise de décision thérapeutique

    “Challenges in ductal carcinoma in situ risk communication and decision-making”

    • Partridge, Ann H.;Elmore, Joann G.;Saslow, Debbie;McCaskill-Stevens, Worta;Schnitt, Stuart J.

    In September 2010, the American Cancer Society and National Cancer Institute convened a conference to review current issues in ductal carcinoma in situ (DCIS) risk communication and decision-making and to identify directions for future research. Specific topics included patient and health care provider knowledge and attitudes about DCIS and its treatment, how to explain DCIS to patients given the heterogeneity of the disease, consideration of nomenclature changes, and the usefulness of decision tools/aids. This report describes the proceedings of the workshop in the context of the current literature and discusses future directions. Evidence suggests that there is a lack of clarity about the implications and risks of a diagnosis of DCIS among patients, providers, and researchers. Research is needed to understand better the biology and mechanisms of the progression of DCIS to invasive breast cancer and the factors that predict those subtypes of DCIS that do not progress, as well as ...


Mots clés : Sein; Dépistage, diagnostic et pronostic (Ressources et infrastructures (Dépistage))

Cet article présente une méthode standardisée pour déterminer la concentration d'hémoglobine dans les tests immunochimiques utilisés pour le dépistage du cancer colorectal

  • A Proposal to Standardize Reporting Units for Fecal Immunochemical Tests for Hemoglobin
    Journal of the National Cancer Institute, sous presse, 2012 (résumé)
    Détails
    Fermer

    Cet article présente une méthode standardisée pour déterminer la concentration d'hémoglobine dans les tests immunochimiques utilisés pour le dépistage du cancer colorectal

    “A Proposal to Standardize Reporting Units for Fecal Immunochemical Tests for Hemoglobin”

    • Fraser, Callum G.;Allison, James E.;Halloran, Stephen P.;Young, Graeme P.

    Fecal immunochemical tests for hemoglobin are replacing traditional guaiac fecal occult blood tests in population screening programs for many reasons. However, the many available fecal immunochemical test devices use a range of sampling methods, differ with regard to hemoglobin stability, and report hemoglobin concentrations in different ways. The methods for sampling, the mass of feces collected, and the volume and characteristics of the buffer used in the sampling device also vary among fecal immunochemical tests, making comparisons of test performance characteristics difficult. Fecal immunochemical test results may be expressed as the hemoglobin concentration in the sampling device buffer and, sometimes, albeit rarely, as the hemoglobin concentration per mass of feces. The current lack of consistency in units for reporting hemoglobin concentration is particularly problematic because apparently similar hemoglobin concentrations obtained with different devices can lead to very ...


Mots clés : Colon-rectum; Dépistage, diagnostic et pronostic (Ressources et infrastructures (Dépistage))

Recherche de publications

Recherche avancée

Widget

 

Archives

Formulaire d’abonnement

Pour recevoir gratuitement chaque nouveau numéro de Nota Bene Cancer par courriel :

S'abonner

Sources

Pour visualiser l'ensemble des sources alimentant le Nota Bene Cancer :

Accéder au portail des sources du NBC

Foire aux questions

Pour trouver les réponses aux questions que vous vous posez sur Nota Bene Cancer :

Accéder à la F.A.Q.